- An unprecedented achievement of a zero pressure gradient
measured when using the VORTX™ device, directly
correlating with a decrease in markers of blood damage.
- The performance of the VORTX™, tested according to a
regulatory guideline, was found to meet 100% of blood oxygenation
requirements at various blood flow rates.
- A significant leap forward in the development of safer, more
effective medical devices designed to minimize patient risk and
improve clinical outcomes.
- U.S. Patent with 94% of claims found to be novel.
RA'ANANA, Israel, March 12,
2024 /PRNewswire/ -- Inspira™Technologies OXY
B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira
Technologies"), a breakthrough medical technology company targeting
to supersede mechanical ventilators, today announced that the
Company's U.S. patent backed technology, the orbiting blood
oxygenation technology (VORTX™) has broken through a significant
technological barrier, meeting 100% of regulatory guideline
requirements for blood oxygenation and carbon dioxide removal, at
various blood flow rates with the pressure gradient on the blood
across the device remaining at zero level. Pressure gradient is
associated with high mechanical shear stress (HMSS), which plays a
dominant role in damaging blood components such as red blood cells,
immune cells, thrombocytes and more. These primary
results for the key endpoints of a new blood oxygenation technology
without the need for fiber membranes and with zero levels of
pressure gradient mark a huge milestone for the Company and for the
INSPIRA™ ART (Gen 2) device.
The Chief Technology Officer of Inspira Technologies, Dr.
Daniella Yeheskely-Hayon, stated: "Our team achieved this
technological breakthrough with the Company's proprietary orbiting
oxygenation technology designed to promote less damaging blood flow
regime and eliminate the need to use the current membrane
fibers-based devices that are associated with increased pressure
differential and high shear stress across the blood oxygenators,
which leads to severe critical clinical complications such as
hemolysis, bleeding, inflammation and blood clots. For me, this is
a very significant day in my career as a scientist."
The advanced experiments demonstrated the primary performance of
the VORTX™ by collecting data on oxygenation, carbon dioxide
removal, and pressures across the device during blood use. The
unique design of the VORTX™ system suggests that scaling up
may result in negligible to zero pressure, even at higher flow
rates. This stands in stark contrast to membrane-based devices,
which typically experience significant pressure drops, leading to
potential damage to the patient's blood.
We firmly believe that Inspira technology will facilitate a
shift away from fiber membrane-based devices towards a technology
that offers excellent gas exchange (i.e., oxygenation and carbon
dioxide removal) without the critical complications associated with
long-term use. Furthermore, transitioning from fiber membrane to
alternative materials will significantly reduce manufacturing costs
and eliminate the global dependence on a single raw material
supplier.
Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies is an innovative medical technology
company in the respiratory treatment arena. The Company has
developed a breakthrough Augmented Respiration Technology
(INSPIRA™ ART), designed to rebalance patient oxygen
saturation levels. This technology potentially allows patients to
remain awake during treatment while reducing the need for highly
invasive, risky, and costly mechanical ventilation systems that
require intubation and medically induced coma. The Company's
products have not yet been tested or used in humans and has not
been approved by any regulatory entity.
For more information, please visit our corporate
website: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses significance of the
VORTX™ and data collected, its belief relating to the
superiority of its technology to membrane-based devices in terms of
sustaining zero to negligible pressure at high flow rates, that the
unique design of the VORTX™ suggests that scaling up may
result in negligible to zero pressure, the belief that the
Company's technology will facilitate a shift away from fiber
membrane-based devices towards gas exchange facilitation
technologies and that transitioning from fiber membrane to
alternative materials will significantly reduce manufacturing costs
and eliminate the global dependence on a single raw material
supplier. These forward-looking statements and their implications
are based solely on the current expectations of the Company's
management and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements. Except as otherwise
required by law, the Company undertakes no obligation to publicly
release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events. More detailed information
about the risks and uncertainties affecting the Company is
contained under the heading "Risk Factors" in the Company's annual
report on Form 20-F for the fiscal year ended December 31, 2022, filed with the U.S. Securities
and Exchange Commission (the "SEC"), which is available on the
SEC's website, www.sec.gov
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Logo -
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-releases-new-data-demonstrating-superiority-of-its-core-technology-across-key-endpoints-of-hmss-indicator-302086654.html
SOURCE Inspira Technologies